Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$10.48 - $16.94 $198,239 - $320,437
18,916 New
18,916 $288,000
Q2 2022

Aug 12, 2022

SELL
$2.09 - $4.02 $23,826 - $45,827
-11,400 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$3.45 - $14.99 $39,330 - $170,886
11,400 New
11,400 $43,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $532M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Mirabella Financial Services LLP Portfolio

Follow Mirabella Financial Services LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirabella Financial Services LLP, based on Form 13F filings with the SEC.

News

Stay updated on Mirabella Financial Services LLP with notifications on news.